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Nonsteroidal anti-inflammatory 
drugs modulate cellular 
glycosaminoglycan synthesis by 
affecting EGFR and PI3K signaling 
pathways
Paweł Mozolewski1, Marta Moskot2, Joanna Jakóbkiewicz-Banecka1, Grzegorz Węgrzyn3, 
Katarzyna Bocheńska1, Bogdan Banecki4 & Magdalena Gabig-Cimińska2
In this report, selected non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and nimesulide, 
and analgesics acetaminophen, alone, as well as in combination with isoflavone genistein as 
potential glycosaminoglycan (GAG) metabolism modulators were considered for the treatment of 
mucopolysaccharidoses (MPSs) with neurological symptoms due to the effective blood-brain barrier 
(BBB) penetration properties of these compounds. We found that indomethacin and nimesulide, but 
not acetaminophen, inhibited GAG synthesis in fibroblasts significantly, while the most pronounced 
impairment of glycosaminoglycan production was observed after exposure to the mixture of nimesulide 
and genistein. Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the 
presence of indomethacin and nimesulide than in the presence of genistein. When examined the 
activity of phosphatidylinositol-3-kinase (PI3K) production, we observed its most significant decrease 
in the case of fibroblast exposition to nimesulide, and afterwards to indomethacin and genistein mix, 
rather than indomethacin used alone. Some effects on expression of individual GAG metabolism-related 
and lysosomal function genes, and significant activity modulation of a number of genes involved in 
intracellular signal transduction pathways and metabolism of DNA and proteins were detected. This 
study documents that NSAIDs, and their mixtures with genistein modulate cellular glycosaminoglycan 
synthesis by affecting EGFR and PI3K signaling pathways.
Glycosaminoglycans (GAGs, formerly called mucopolysaccharides), endogenous organic compounds synthe-
sized in most tissues of human body, play important roles in fundamental biological processes, mostly by binding 
to variety of proteins1. In normal cells there is a constant turnover of GAGs in lysosomes, which is mediated 
by specific acid hydrolases. However altered GAG metabolism is responsible for multiple cell, tissue and organ 
damages throughout the body. Currently identified diseases of this type include mucopolysaccharidoses (MPSs), 
a group of genetically determined metabolic disorders. Depending on specific enzymatic defects, in various types 
of MPS, lysosomal storage of particular GAG or their combination occurs. The growing understanding of the eti-
ology of these diseases has led to the development of specific therapeutic approaches. The methods rely on direct 
(enzyme replacement therapy - ERT) or indirect (hematopoietic stem cells’ transplantation - HSCT, gene therapy 
- GT) delivery of the appropriate lysosomal enzyme into the patient. Research has shown that supplementing the 
absence or deficiency of active enzyme directly or indirectly via the above-mentioned treatment methods can 
indeed cause degradation of accumulated glycosaminoglycans, which in turn translates into improved clinical 
status of a patient2. However, these approaches have their specific limitations3. For example, the major problem 
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of ERT concerns the inefficient enzyme dissemination to all occupied sites in the body, including its ineffective 
delivery to the central nervous system (CNS) due to an ineffective delivery of proteins through the blood-brain 
barrier2. Another group of treatment includes a method based on reduced synthesis of substrate (called substrate 
reduction therapy - SRT)4. This strategy relates to the partial inhibition of enzymes of the lysosomal substrate 
biosynthetic pathway by low molecular weight inhibitor, leading to reduction of these de novo synthesized sub-
strates. The purpose of this is to restore in pathologically changed cells the equilibrium between the processes of 
synthesis and degradation of these substrates. This type of approach tries to apply in various cases of lysosomal 
storage diseases, including the neurodegenerative disorders4.
Recently, studies on the implementation of the concept of substrate reduction therapy in the treatment of MPS 
were conducted5,6. The work has been performed on the use of various compounds to lower yield of glycosamino-
glycans and being effective in treatment of neuronopathic forms of MPSs due to their ability to cross the BBB. 
So far several flavonoids were tested, and among them, genistein has been studied most intensively, and it was 
proposed that this compound can downregulate GAG production by blocking phosphorylation of the epidermal 
growth factor (EGF) receptor (EGFR), thus impairing a signal transduction pathway necessary for activation of 
genes coding for enzymes involved in this anabolic process7–9. Indeed, we identified the genistein-mediated gene 
network regulating not only GAGs biosynthesis, but also degradation of these macromolecules, taking into con-
sideration the entire lysosomal metabolism10–12. This work led us to revise the action of the other EGFR inhibitors, 
which could be considered as putative drugs in MPS treatment, even more efficient in treating the neurological 
symptoms. This will be a milestone in the development of substrate reduction therapy and crucial in view of fact 
that the SRT is a promising strategy for treatment of mucopolysaccharidoses, and what is most important, it gives 
chance to be effective for their neurodegenerative forms, for which no treatment is available at the moment. The 
agents being candidates should be relatively weak inhibitors, while GAGs are compounds necessary for devel-
opment and proper function of many tissues and organs, thus, complete or very strong inhibition of their prod-
ucts would not be desired, especially in children treatment. Additionally, SRT for inherited metabolic diseases, 
like MPS, must be considered as a long-term therapy, potentially for the whole life, thus agents with at most 
marginal adverse effects are considered. The investigations showed that acetaminophen (N-(4-hydroksyfenylo)
acetamid), indomethacin (2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid) 
and nimesulide N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide) are substances remarkably inhibit-
ing glycosaminoglycans synthesis13,14. While the first one is analgesics, the two others belong to nonsteroidal 
anti-inflammatory drugs (NSAIDs), commonly used for the reduction of pain, fever, inflammation and stiffness. 
This information, together with their analgesic and anti-inflammatory action speaks for their potential use in 
treatment of diseases, such as mucopolysaccharidoses, usually accompanied by strong pain and inflammation. 
Therefore, in this study, the above mentioned compounds, as well as their mixtures with genistein (previously 
investigated in the context of lysosomal modulation10,11), were selected and applied for investigation of their 
effects on GAG metabolism in cultures of healthy and MPS cells. The implementation of a cell culture model, that 
shows a finite proliferative capacity has the advantage of providing a controlled environment to investigate a wide 
variety of cellular phenomena. It has also the inherent limitation of isolating cells from the regulatory elements 
that might be provided by other types of cells. Among different cells types (such as keratinocytes, melanocytes, 
lymphocytes, glial, lens and endothelial cells), fibroblasts from normal and MPS individuals exhibit most limited 
replicative life span in the culture, and therefore, remain a powerful tool for our studies.
Materials and Methods
Study approval. All methods were carried out in accordance with guidelines and regulations included in 
the official documents of the University of Gdańsk. All experimental protocols were approved by the Research 
Committee of the Department of Molecular Biology of the University of Gdańsk.
Skin fibroblasts were obtained from humans who had given informed consent at the Children’s Memorial 
Health Institute, Warsaw, Poland.
Cell lines, culture media and reagents. Human Dermal Fibroblasts, adult (HDFa) (Cascade Biologics, 
Portland, USA) and MPS fibroblasts types IIIA, IIIB and VI (Children’s Memorial Health Institute, Warsaw, 
Poland) were cultured in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific Inc., Paisley, UK) supple-
mented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic solution (Sigma-Aldrich Co. LLC., St. 
Louis, USA) at 37 °C in a humidified atmosphere containing 5% carbon dioxide (CO2). Jurkat T cells (American 
Type Culture Collection, Manassas, USA) were grown in RPMI-1640 medium (Thermo Fisher Scientific Inc., 
Paisley, UK) supplemented with 10% FBS and 1% antibiotic/antimycotic solution (Sigma-Aldrich Co. LLC., St. 
Louis, USA) at 37 °C in a humidified atmosphere containing 5% CO2. Viability of Jurkat T cells was assessed 
using MUSE® Cell Analyzer (Merck Millipore, Germany) using a Count & Viability Assay Kit (Merck Millipore, 
Germany) before subculturing or experimental procedure. Wortmannin (Sigma-Aldrich Co. LLC., St. Louis, 
USA) prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co. LLC., St. Louis, USA) and stored at a stock 
concentration of 2 mM at −20 °C was used for inhibition of constitutively active PI3K signaling pathway in Jurkat 
T cells. Used in this study NSAIDs, i.e. acetaminophen, indomethacin, nimesulide (Sigma-Aldrich Co. LLC., 
St. Louis, USA), and isoflavone genistein (Pharmaceutical Research Institute Warsaw, Poland) were dissolved in 
DMSO, and added in the indicated final concentrations, in the case of NSAIDs as stated in literature and reports 
on the clinical usage13,15–18, while for genistein as determined in our previous studies on cell cultures8.
Cytotoxicity and proliferation assays. Cell viability was assessed with MTT assay. For this, 6 × 103 
cells per well (in cytotoxicity assay) or 103 cells per well (in proliferation assay) were seeded in flat-bottomed 
96-well plates and grown overnight at 37 °C and 5% CO2. Then the growth medium was substituted with fresh one 
supplemented with tested compounds at appropriate concentrations or 0.05% DMSO as control (Ctrl). 
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After period of time (i.e. 24 and 48 h to test cytotoxicity, or for 7 days to test cell proliferation), medium was 
replaced with RPMI-1640 (Sigma-Aldrich Co. LLC., St. Louis, USA) supplemented with MTT (3-[4,5-dimet
hylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 1 mg/ml) (Sigma-Aldrich Co. LLC., St. Louis, USA) for 
another 4 h. The purple formazan crystals were dissolved in 150 ml of 100% DMSO, and absorbance was deter-
mined at 570 nm using Wallac 1420 Multilabel Counter (Perkin Elmer Inc., MA, USA).
Measurement of kinetics of GAG synthesis. Glycosaminoglycan synthesis was estimated by measure-
ment of 35S or 3H incorporation into GAG chains. Cells were plated in a number of 2 × 104 per well in 48-well plate 
and incubated overnight to allow the attachment. Next, cells were treated for 48 hours in standard DMEM sup-
plemented with appropriate amounts of particular NSAIDs, genistein, mixtures of selected NSAIDs with genis-
tein or DMSO only (Ctrl). After 48 h of incubation, cells were labelled for 24 hours with 20 mCi/ml of H2[35S]O4 
or 10 mCi/ml of 3H-GlcN (Hartmann Analytic GmbH, Braunschweig, Germany) in growth medium without inor-
ganic sulfates (Minimum Essential Medium Eagle, Joklik’s modified, Sigma-Aldrich Co. LLC., St. Louis, USA) 
or growth medium without glucose (Thermo Fisher Scientific Inc., Paisley, UK) mixed with standard DMEM 
medium (1:1) supplemented with tested compounds or DMSO. Next, cells were washed six times with Dulbecco’s 
phosphate-buffered saline (DPBS, Thermo Fisher Scientific Inc., Paisley, UK) and digested for 3 hours at 65 °C 
with 0.5% papain (Sigma-Aldrich Co. LLC., St. Louis, USA) (prepared in 200 mM phosphate buffer [Na2HPO4 - 
NaH2PO4], pH 6.4, containing 100 mM sodium acetate, 10 mM Na2EDTA and 5 mM L-cysteine). Incorporation 
of radioactive precursors was measured in a MicroBeta2 scintillation counter (Perkin Elmer Inc., MA, USA) and 
Quant-iT™ PicoGreen® dsDNA Reagent (Thermo Fisher Scientific Inc., Paisley, UK) was used to determine 
DNA concentration in papain digested samples. Incorporation of radioactive precursors was calculated per DNA 
amount (cpm/ng of DNA) and expressed as relative to control cultures (treated with 0.05% DMSO only).
To study the effects of a combination of tested compounds in order to provide evidence of a significant superi-
ority compared to the single agents the Combination Index (CI) with the use of the Bliss Independence model was 
determined19,20. It is based on the principle that drug effects are outcomes of probabilistic processes and assumes 
that drugs act independently in such a manner that neither of them interferes with the other (different sites of 
action), but each contributes to a common result. CI is recognized as the standard measure of combination effect 
that indicated a greater (CI < 1), lesser (CI > 1) or similar (CI = 1) effect than the expected additive effect.
EGFR and PI3K phosphorylation analysis. Efficiency of phosphorylation inhibition of the epider-
mal growth factor receptor (EGFR) or phosphoinositide 3-kinase (PI3K) pathway was assessed using MUSE® 
Cell Analyzer (Merck Millipore, Germany) using a Millipore’s Muse™ Activation Dual Detection kits (Merck 
Millipore, Germany). HDFa cells were seeded in 6-well plates at a density of 2 × 105 per well. Following an over-
night incubation, standard growth medium was substituted with the medium containing 0.05% DMSO only, 
supplemented with 100 ng/ml EGF in 0.05% DMSO, or with 100 ng/ml EGF in 0.05% DMSO and particular tested 
compounds at the indicated final concentrations21. After 24 hours EGFR pathway activation was determined 
by Muse® EGFR-RTK Activation Dual Detection kit (Merck Millipore, Germany) by using a phospho-specific 
anti-phospho-EGFR (Tyr1173)-Alexa Fluor®555 and an anti-EGFR-PECy5 according to the manufacturer’s 
protocol. Similarly, PI3 kinase pathway activation was assessed using an anti-phospho-Akt (Ser473), Alexa 
Fluor®555 and an anti-Akt, PECy5 provided in the PI3K Activation Dual Detection kit (Merck Millipore, 
Germany). Additionally, Jurkat T cells treated with 0.5 mM wortmannin were used as a control of PI3K activation 
status determination.
Total RNA extraction. For transcriptomic analyses 1 × 105 cells were seeded and grown for 24 h. Then, 
the medium was substituted with either NSAIDs-free one, containing DMSO (Ctrl), or the one supplemented 
with appropriate amounts of tested drug, genistein or mixture of drug and genistein. Total RNA was extracted 
from cells using the High Pure RNA Isolation Kit (Roche Applied Science, IN, USA) and quantified with the 
Quant-itTM RiboGreen® assay kit (Thermo Fisher Scientific Inc., Paisley, UK) following the manufacturer’s 
instructions. In addition, the quality of each RNA sample was assessed using the RNA 6000 Nano Assay on the 
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., CA, USA).
DNA microarray processing and real-time quantitative RT-PCR assays for mRNA analysis. 
Whole genome microarray analysis of three biological replicates was performed using Illumina’s Human HT-12v4 
Expression BeadChips, targeting more than 25,000 genes with more than 48,000 probes (Illumina Inc., CA, 
USA), for all tested conditions. BeadChips were scanned using an Illumina BeadArray Reader and the Bead Scan 
Software (Illumina Inc., CA, USA). The quality of microarray data was controlled by examining raw and adjusted 
intensity histograms. The assay performance and data extraction was done according to Moskot et al.10 All gene 
expression data have been deposited in the NCBI Gene Expression Omnibus (GEO series accession number 
GSE63239), according to the MIAME (minimum information about a microarray experiment) standards. An 
overview of experiment performance was gained by clustering samples using a correlation metric (Illumina® 
BeadStudio Data Analysis software). The Pearson correlation coefficient method was used to calculate “expres-
sion distance values” across experiments and to group samples that have similar expression patterns. The values 
ranging between 0.98 and 0.99 for biological replicates indicate a high degree of reproducibility and strong corre-
spondences between expression profiles.
Quantitative real-time Reverse Transcription PCR (real-time qRT-PCR) was performed to measure the 
mRNA levels of the studied genes. Total RNA was reverse-transcribed into cDNA using Transcriptor First Strand 
cDNA Synthesis Kit (Roche Applied Science, IN, USA), according to the manufacturer’s instructions. Real-time 
qRT-PCR was carried out with Real-Time ready Custom Panel (cat. no. 05532914001, config. no. 100093799; 
Roche Applied Science, IN, USA) and the LightCycler® 480 Probes Master (Roche Applied Science, IN, USA) 
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using the Light Cycler 480 II detection system (Roche Applied Science, IN, USA). Expression values were nor-
malized against three control genes ACTB, SDHA and YWHAZ of constant expression level (2−ΔΔct method). 
Determination of reference genes for real-time qRT-PCR was assessed using commercially available RealTime 
ready Human Reference Gene Panel (cat no. 05339545001, Roche Applied Science, IN, USA). Moreover, sta-
tistical analyses of the normalized gene expression data were performed in Prism (GraphPad). For both DNA 
microarray and real-time qRT-PCR analyses, a fold change (FC) greater or equal to 1.3 and below and equal 
0.7 was considered as a relevant criterion for genes being significantly differentially expressed, with a p value of 
<0.05.
Gene Ontology and Gene Set Enrichment studies. The transcriptomic analysis was conducted through 
combining gene set enrichment analysis (GSEA)22, with the use of GOrilla23 and REViGO (visual interaction gene 
network analysis)24 tools for reconstructing crucial molecular networks and target genes identification. For GSEA 
study goals Reactome was used as reference database for ontology distribution with FDR q-value below 0.1 overall 
as a limitation for ontology selection. Tests for enrichment of genes with shared Biological Process Gene Ontology 
(GO) terms were performed using the online tool GOrilla. REViGO was used to eliminate redundant GO terms, 
and multiple-test correction for significant GO. Genes exhibiting fold change ≥1.3 and below and equal 0.7 with 
a p value less than 0.05, defined as differential expressed genes (DEGs), were examined.
Results
Selection of analgesic and nonsteroidal anti-inflammatory drugs and study of their cytotoxic 
and antiproliferative activity. It has been previously demonstrated that acetaminophen, indomethacin 
and nimesulide are among analgesics and NSAIDs which inhibit GAG synthesis13,14,25. Moreover, mixtures of 
those compounds with genistein, flavonoid responsible for impairment of production and enhancement of deg-
radation of glycosaminoglycans6,10,11, were included in this work in order to see whether they might result in even 
more effective reduction of GAG accumulation than the use of any of these compounds alone. The concentrations 
of acetaminophen (5–500 mM), indomethacin (1.5–50 mM), and nimesulide (0.3–100 mM) used are close to clini-
cally relevant molar concentrations, while genistein of 100 mM as previously applied6,10,11.
We first tested selected drugs in order to establish their cytotoxicity and antiproliferative activity in cul-
tured fibroblasts. For this, we measured metabolic activity of HDFa, MPS IIIA, IIIB and VI cells treated with 
different concentrations of acetaminophen (5, 25, 100, and 500 mM), indomethacin (1.5, 5, 15, and 50 mM), or 
nimesulide (0.3, 2, 10, and 100 mM) for different periods of time (24, 48 h, and 7 days). This study demonstrated 
that 24 and 48 h treatment with clinically achievable low concentrations of tested compounds has little cytotoxic 
effect (Fig. 1). Additionally, no remarkable inhibitory effect of particular compounds on fibroblasts growth after 
7 days was visible, while clear antiproliferative activity was observed for mixtures used, i.e. both indomethacin or 
nimesulide with genistein (Fig. 1).
Assessment of the effectiveness of inhibition of GAG synthesis by acetaminophen, indometh-
acin, nimesulide, and their mixtures with genistein. The level of GAG synthesis was estimated by 
measurement of [35S]O42− or [3H]GlcN uptake in both HDFa and various types of MPS fibroblasts. Tested com-
pounds were added individually at the final concentration of 20, 100, and 500 mM for acetaminophen, 0.4, 2, 
and 10 mM for indomethacin and 1, 5, and 25 mM for nimesulide, 100 mM for genistein, or applied as mix of 10 mM 
indomethacin and 100 mM genistein, or 25 mM nimesulide and 100 mM genistein to cell culture. We found that two of all 
tested compounds, i.e. indomethacin and nimesulide, but not acetaminophen, revealed ability to inhibit significantly 
GAG synthesis in HDFa, MPS IIIA and VI (Fig. 2). The most pronounced impairment of glycosaminoglycan produc-
tion measured by estimation of the amount of incorporated 35S was observed after 72-hour exposure to nimesulide 
and genistein mixture in HDFa (48% decrease) and MPS IIIA (40% reduction). Furthermore, statistically significant 
differences in GAG synthesis relative to untreated cells were documented by estimation of the amount of incorpo-
rated 35S with some exceptions as follows: (i) at the level of around 30% reduction for HDFa treated for 72 hours with 
25 mM nimesulide (when both radioactive precursors applied), HDFa and MPS IIIA treated for 72 hours with 100 mM 
genistein, and MPS VI in the presence of 10 mM indomethacin; (ii) at the level of 25% decrease for HDFa treated for 
72 hours with 10 mM indomethacin and for 7 days with 25 mM nimesulide, as well as for MPS VI exposed to 25 mM 
nimesulide for 72 hours; and (iii) at the level of 15–20% decline for HDFa treated for 72 hours with 1 mM nimesulide 
(glucosamine, D-[1-3 H] incorporation), and for 7 days with 5 mM nimesulide, as well as for MPS IIIA exposed to 25 mM 
nimesulide for 72 h. Interestingly, acetaminophen stimulated rather than inhibited GAG synthesis (Fig. 2). In addition, 
the Combination Index (CI) with the use of the Bliss Independence model was determined for the action of tested 
mixtures in HDFa and MPS IIIA fibroblasts. For both cell lines the CI value was 1.9 in the case of indomethacin and 
genistein combination indicating an antagonism. When the mixture of nimesulide and genistein was used, the CI was 
equal to 1.0, resulting in an additive effect.
Inhibition of phosphorylation of EGF receptor in the presence of indomethacin, nimesulide and 
genistein. To test whether compounds used in this study impair GAG synthesis by the same mechanism as that 
proposed for genistein, we measured efficiency of phosphorylation of EGFR in the presence and absence of inves-
tigated NSAIDs, i.e. indomethacin and nimesulide, effectively inhibiting GAG synthesis in fibroblasts. In addition, 
tests with the use of mixture of indomethacin and genistein, and also nimesulide and genistein were performed. The 
extent of EGFR pathway activation by measuring EGFR phosphorylation relative to the total EGFR expression in 
given cell population was investigated. By doing such, the levels of both the total and phosphorylated protein were 
measured simultaneously in the same cell, resulting in a normalized and accurate measurement of EGFR activation 
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Figure 1. Cytotoxic and antiproliferative activity of acetaminophen (A), indomethacin (I), and nimesulide 
(N), respectively, in HDFa (panel A), MPS IIIA (panel B) and IIIB (panel C), and MPS VI (D) fibroblasts. 
Sections E1 and E2 stand for viability of HDFa and MPS IIIA cells treated with mixtures of indomethacin (I) 
and genistein (G), and also nimesulide (N) and genistein (G). Statistically significant differences in cell viability 
relative to control cells (treated with 0.05% DMSO only) are indicated with * for p < 0.05, ** for p < 0.01. 
Statistical analysis was performed using ANOVA with Tukey’s HSD Post Hoc test.
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after drug stimulation. We found that both NSAIDs tested separately revealed statistically significant inhibition of 
EGFR phosphorylation, even more effective than that of genistein, or compounds’ combinations (Fig. 3).
PI3K activity decrease in fibroblasts treated with NSAIDs and genistein. In this part of the work 
we studied further how the inhibition of EGFR phosphorylation by investigated NSAIDs influences the activity 
of phosphatidylinositol-3-kinase, a downstream effector of EGF receptor, in fibroblasts treated with particular 
indomethacin and nimesulide alone or with their mixture with genistein. When examined the activity of PI3K 
produced we observed its most significant decrease in the case of cell exhibition to nimesulide. Indomethacin in 
combination with genistein resulted in more effective inhibition of PI3K activity than used alone, however still 
less pronounced when compared to nimesulide (Fig. 4).
Activity of genes involved in GAG and lysosomal metabolism, prostaglandin synthesis and 
intracellular signaling pathways. Microarray analyses were performed on HDFa cells after 24 and 48 h 
of either vehicle or particular drug treatment, i.e. with 2 and 10 mM indomethacin, or 5 and 25 mM nimesulide. 
Figure 2. Relative level of glycosaminoglycan synthesis in HDFa, MPS IIIA, IIIB and VI fibroblasts 
after 72 h or 7-day treatment with different concentrations of acetaminophen, indomethacin, 
nimesulide, genistein (100 μM), mix 1 (10 μM indomethacin + 100 μM genistein), and mix 2 (25 μM 
nimesulide + 100 μM genistein), measured by incorporation of [35S]O42− or [3H]GlcN. Radioactivity of 
incorporated precursors was quantified in a scintillation counter, calculated per DNA amount [dpm/ng DNA], 
and expressed as the percentage of control (‘Ctrl’ stands for cell culture treated with 0.05% DMSO). Statistical 
analysis was performed by using ANOVA with Tukey’s HSD Post Hoc test. Significance values are indicated 
with * for p < 0.05, ** for p < 0.01.
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In general, the microarray studies revealed that the fibroblasts responded to this treatment rather with minor 
changes in global expression profiles of only few dozen of genes, slightly modulating transcript level of genes 
involved in GAG metabolism pathway and lysosomal function, affecting however a number of genes related to 
different signal transduction pathways and metabolism of DNA and proteins, substantially when high concentra-
tions of the NSAIDs were applied.
We used a real-time quantitative RT-PCR approach to examine in more detail the expression patterns of genes 
involved in GAG metabolism, as well as in lysosome biogenesis and function, whose activities were modulated 
in fibroblasts at tested conditions, as observed in microarray studies. Because significant changes in the activity 
of these genes were generally visible to the cells treated with 25 mM nimesulide, 100 mM genistein, and the mix 
of these two compounds, we implemented such conditions for real-time qRT-PCR analyses. Among 45 genes 
covered by Real Time ready Custom Panel, 7 of GAG metabolism pathways (5 of GAG synthesis and 2 of GAG 
degradation) and 7 sequences coding for lysosomal proteins (except for these 2 of GAG degradation), all reveal-
ing modulated activity in transcriptomic analyses, were detected (Table 1). Interestingly, we found an increase 
in mRNA level of TFEB (gene coding for transcription factor EB; 1.3 ± 0.1 v. ACTB and 1.7 ± 0.2 v. YWHAZ for 
mix of 10 mM indomethacin and 100 mM genistein, 1.7 ± 0.1 v. ACTB and 1.6 ± 0.0 v. YWHAZ for mix of 25 mM 
nimesulide and 100 mM genistein), and MTOR (gene coding for Serine/Threonine-Protein Kinase MTOR; 
1.3 ± 0.2 v. ACTB and 1.6 ± 0.2 v. YWHAZ for mix of 10 mM indomethacin and 100 mM genistein, 1.5 ± 0.1 v. 
ACTB and 1.4 ± 0.1 v. YWHAZ for mix of 25 mM nimesulide and 100 mM genistein), and no changes in EGFR 
transcript amount compared with the untreated samples, in HDFa cells treated for 24 h with both mixtures, 10 mM 
indomethacin with 100 mM genistein, and 25 mM nimesulide with 100 mM genistein, in respect to ACTB and 
YWHAZ references, correspondingly (data not shown). At the same time, we did not notice any significant var-
iations in the activity of all those three genes in cells treated individually with indomethacin or nimesulide (data 
not shown).
Moreover, no transcriptomic data regarding modulation of expression of prostaglandin synthesis were availa-
ble due to the problem with low level analysis being related to elimination of the results for these transcripts after 
background adjustment. This could have resulted from the use of uninflamed, wild type HDFa fibroblasts, i.e. 
not induced by inflammatory stimuli. Though, we used a real-time quantitative RT-PCR approach to examine 
in more detail the expression patterns of two prostaglandin synthase genes, PTGS1 and PTGS2, in fibroblasts 
exposed not only to 10 mM indomethacin or 25 mM nimesulide as it was in the case of microarray analysis, but 
also to their mixtures with 100 mM genistein. We found that indomethacin, but not nimesulide induced a 1.3-fold 
decrease of PTGS1 mRNA level, while PTGS2 expression was down-regulated by nimesulide, not however by 
indomethacin, when compared with the non-treated counterpart by using both the ACTB and YWHAZ reference 
control genes. Peculiarly, the analysis showed that both genes PTGS1 and PTGS2 were however significantly 
enriched in their transcript level in response to the compound combinations’ treatment of cells.
Figure 3. Effects of investigated NSAIDs and their mixtures with genistein on tyrosine kinase activity 
of EGF receptor (EGFR). HDFa cells were treated with 0.05% DMSO and used as control (A, left panel), 
with 100 ng/ml EGF in 0.05% DMSO (A, right panel), or with 100 ng/ml EGF in 0.05% DMSO and particular 
compounds alone such as 100 mM genistein (B), 10 mM indomethacin (C), 25 mM nimesulide (D), or in mixtures 
of 10 mM indomethacin and 100 mM genistein (E), or 25 mM nimesulide and 100 mM genistein (F). Percentage of 
inactivated cells, activated cells (via EGFR phosphorylation) and non-expressing cells was determined for each 
experimental condition. Data represent the average and standard deviation of three independent experiments. 
Statistical analysis was performed by using one-way ANOVA and the Tukey’s HSD Post Hoc test. Values of 
p < 0.05 (*) or p < 0.01 (**) are indicated.
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In addition, our studies revealed that selected NSAIDs and/or their combination with genistein can significantly 
modulate mRNA level of genes coding for products involved in regulation of cellular signaling pathways, and DNA 
and protein metabolism (Fig. 5 and Table 2). Gene Ontology analyses performed with the GOrilla tool of microarray 
data revealed that at the top of the list of NSAID-regulated genes, were those mainly involved in metabolic processes 
(for both 10 mM indomethacin and 25 mM nimesulide 24 h treatment) in the cell (Fig. 5). Accordingly, GSEA con-
ducted on the Reactome pathways showed a significant enrichment of signal transduction cascades genes (involved 
mainly in the Wnt, TCR, SCF/c-kit associated with PI3K signaling), and among DNA and protein metabolism genes, 
regulated by 10 mM indomethacin, and also 25 mM nimesulide, after 24 h exposition (Table 2).
Discussion
This work exploits and expands on recent breakthroughs in the understanding of cellular cross-talk to develop novel 
therapeutic approaches based on the use of analgesic nonsteroidal anti-inflammatory drugs to treat rare inherited 
lysosomal diseases, such as mucopolysaccharidoses caused by altered glycosaminoglycan metabolism. The encour-
aging results of research on the molecular mechanism of isoflavone genistein-mediated impairment of GAG pro-
duction prompted us to continue the study on the implementation of the non-enzymatic SRT using GAG synthesis 
inhibitors to treat MPS, especially those with neurological symptoms7,10,11. Furthermore, the latest investigations 
exhibited that among different analgesics and NSAID compounds acetaminophen, indomethacin and nimesulide 
are substances remarkably inhibiting GAG synthesis13,14. It has been shown that the reason for this glycosamino-
glycan level reduction is a deficiency of cellular sulphates, a key factor balancing the production and degradation of 
GAGs, resulting from NSAID medication with side-effect in form of sulphate depletion, which in turn takes place 
in the treatment of arthritis25–27. There is different matter in the case of patients suffering from mucopolysacchari-
dosis. The excess of GAGs, due to lack of or significantly reduced activity of one of the enzymes responsible for deg-
radation of these compounds, affects cells, tissues, organs, and consequently the whole body. Thus, the performance 
of GAG synthesis reduction through the use of agents causing the sulphate depletion in the human body may yield 
in a related effect to that observed in the case of genistein. It is reported in the literature that the main mechanism 
of action of indomethacin and nimesulide is the inhibition of prostaglandin synthesis by blocking the activity of 
the enzyme cyclooxygenase (COX) isoforms, officially known as prostaglandin-endoperoxide synthase (PTGS) 
isoforms, COX-1 (PTGS1; non-selectively blocked by indomethacin), COX-2 (PTGS2; non-selectively blocked 
by indomethacin and selectively blocked by nimesulide) and/or COX-3 (selectively blocked by acetaminophen), 
which in turn leads to reduced signs of inflammation28. Another work, describing stimulation of angiogenesis, 
cell proliferation and differentiation in carcinogenesis by prostaglandins, indicated their additional function as 
activators of intracellular signaling pathway through EGF receptor26. Based on this, a hypothesis can be considered 
that the reduction of prostaglandin level, resulting from the inhibition of their synthesis in the cell exposed to the 
above substances responsible for the COX activity decrease, might lead to the inhibition of EGF receptor activity, 
thereby blocking the cellular signal transduction process essential for the expression of genes encoding the relevant 
enzymes involved in the metabolism of GAGs. However, this phenomenon has remained unclear. Therefore, we 
intended to validate the extent of action of not only flavonoids, but also selected drugs, and to learn interactions at 
the molecular level in terms of modulation of cellular responses by these substances.
As acetaminophen, indomethacin and nimesulide belong to drugs routinely used in medication, their cytotox-
icity and anti-proliferation features are already widely documented and are consistent with those obtained in our 
work (Fig. 1). Moreover, the properties concerning the impairment of GAG synthesis via all three selected for this 
work compounds were verified, when used alone and in combination with genistein (Fig. 2). Interestingly, most 
significant inhibition of glycosaminoglycan production was observed in cells treated with a mix of nimesulide 
Figure 4. Activity of phosphatidylinositol-3-kinase (PI3K) in HDFa treated with 0.05% DMSO only  
(Ctrl 1), 10 μM indomethacin, 25 μM nimesulide, 100 μM genistein, or mixture of 10 μM indomethacin and 
100 μM genistein, or 25 μM nimesulide and 100 μM genistein. Two additional control assays were included, 
Jurkat cells untreated (Ctrl 2) or treated with wortmannin (Ctrl 3). Percentage of inactivated cells, activated cells 
(via PI3K phosphorylation) and non-expressing cells was determined for each experimental condition. The 
results presented are average values obtained from three different experiments with bars indicating standard 
deviation. Statistical analysis was performed by using one-way ANOVA and the Tukey’s HSD Post Hoc test. 
Statistically significant differences in cell viability relative to control cells (treated with 0.05% DMSO only) are 
indicated with * for p < 0.05, ** for p < 0.01.
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and genistein, resulted in an additive effect of these two compounds. The question remains what is the molecular 
mechanism by which the tested compounds reduce efficiency of GAG synthesis. It is known from the literature 
that analgesic and nonsteroidal anti-inflammatory drugs inhibit synthesis of prostaglandins28, and that prosta-
glandins function in cells as activators of intracellular signaling pathway through EGF receptor29. On the other 
hand, results of our previous studies suggested that genistein impairs GAG synthesis due to its inhibitory effect on 
Enzyme name Enzyme function Gene name
Microarray Real-time qRT-PCR
FC ± SD
Nimesulide Genistein* Genistein Nimesulide + Genistein
Acid phosphatase 5
conversion of orthophosphoric 
monoester to alcohol and 
orthophosphate
ACP5 1.0 ± 0.3 1.6 ± 0.1 1.3 ± 0.1 1.7 ± 0.4
Aspartylglucosaminidase catabolism of N-linked oligosaccharides of glycoproteins AGA 1.2 ± 0.1 1.9 ± 0.5 1.2 ± 0.1 1.5 ± 0.1
Arylsulfatase G
hydrolyze sulfate esters from 
sulfated steroids, carbohydrates, 
proteoglycans, and glycolipids
ARSG n.d. 1.2 ± 0.4 1.9 ± 0.1 1.6 ± 0.2
Acid ceramidase 1 degradation of ceramide into sphingosine and free fatty acid ASAH1 1.3 ± 0.2 1.7 ± 0.8 1.4 ± 0.2 1.6 ± 0.2
Chondroitin Sulfate Synthase 3 GAG synthesis, chain polymerization CHSY3 n.d. 0.9 ± 0.2 0.7 ± 0.1 1.7 ± 0.2
Cathepsin K bone remodeling and resorption CTSK n.d. 1.2 ± 0.2 1.2 ± 0.1 1.8 ± 0.1
Exostosin Glycosyltransferase 1 GAG synthesis, chain polymerization EXT1 n.d. 0.6 ± 0.2 0.5 ± 0.0 0.5 ± 0.0
Alpha glucosidase degradation of glycogen to glucose GAA n.d. 1.6 ± 0.7 1.3 ± 0.3 1.4 ± 0.4
Hexosaminidase A degradation of the ganglioside GM2 HEXA n.d. 1.4 ± 0.2 1.0 ± 0.1 1.3 ± 0.3
Heparan Sulfate 
Sulfotransferase 3A1 GAG synthesis, chain modyfication HS3ST3A1 n.d. 0.5 ± 0.2 0.7 ± 0.1 0.6 ± 0.1
Hyaluronoglucosaminidase 3 degradation of hyaluronan HYAL3 n.d. 1.7 ± 0.5 0.6 ± 0.0 0.6 ± 0.1
Beta mannosidase N-linked glycoprotein oligosaccharide catabolism MANBA 1.0 ± 0.3 2.4 ± 0.8 1.7 ± 0.2 2.2 ± 0.3
Sialyltransferase 4B GAG synthesis, chain polymerization ST3GAL2 1.1 ± 0.2 0.6 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
Xylosyltransferase I GAG synthesis, chain initiation XYLT1 1.1 ± 0.1 0.6 ± 0.2 0.3 ± 0.1 0.4 ± 0.1
Table 1.  Expression patterns of GAG metabolism- and lysosome-associated genes in 25 μM nimesulide, 
100 μM genistein and mixture of them, for 24 h treated HDFa fibroblasts analyzed with microarray 
and real-time qRT-PCR custom panel. Values represent fold change (0.7 ≥ FC ≥ 1.3 for at least one of the 
conditions tested, n ≥ 3, with the p-value < 0.05), and denote differences for samples treated with tested 
compound or their mixture, against untreated samples, with respect to reference mRNA expression at a constant 
level. n.d. stands for no data available, as no transcriptomic data regarding modulation of the expression of these 
genes were available due to the problem with low level analysis being related to elimination of the results for 
these transcripts after background adjustment. *Stands for result based on raw data from Moskot et al.11.
Figure 5. Significantly overrepresented GO terms, reflecting biological processes upon 10 μM 
indomethacin (10 μM I) or 25 μM nimesulide (25 μM N) treatment for 24 hours of HDFa cells, with false 
discovery rate (FDR) <0.1, fold change ≥1.3 and below and equal 0.7, and p < 0.001. 
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the kinase activity of the epidermal growth factor receptor (EGFR)7. At this time, we showed that indomethacin 
and nimesulide can inhibit EGFR and PI3K signaling cascades (Figs 3 and 4). It appears that agents that target the 
EGFR/PI3K axes and signaling cascades show a considerable promise for treatment of MPS patients.
Our recent findings provided information on genistein targetome responsible for modulation of expression 
of GAG metabolism and lysosomal biogenesis and function genes10,11. In the work reported here, in turn, we 
observed that indomethacin and nimesulide can downregulate glycosaminoglycan production by blocking phos-
phorylation of EGF receptor (Figs 2 and 3), thus possibly impairing a signal transduction pathway necessary 
for activation of genes coding for enzymes involved in this anabolic process. The reduction in EGFR activity by 
tested NSAIDs, even more effective than by genistein (Fig. 3), may also be associated with the modulation of 
expression of genes which products act as activators of various intracellular signaling pathways. It was therefore 
interesting to study the effect of selected NSAIDs on cell transcriptome, with particular attention paid to GAG 
and lysosome-related genes’ activities, as well as to genes involved in synthesis of prostaglandins and various 
intracellular signaling pathways. We noticed some changes in expression of particular GAG metabolism-related 
and lysosomal function genes, with significant variation in the activity of several transcripts linked to intracellular 
signal transduction pathways and metabolism of DNA and proteins (Fig. 5, Tables 1 and 2). However, it should be 
noted at this point that essentially a rather subtle effect of the tested substances on the global activity of genome of 
human dermal fibroblasts was detected. These observations seem to be valuable particularly in the context of the 
safety in use of these compounds for humans.
The deregulation of GAGs may concern either all types of GAGs or some of them, depending on the agent 
being used. Our studies showed that the tested compounds, i.e. indomethacin, nimesulide and genistein exhibit 
Reactome overrepresented pathway No. of genes NES FDR q-val
10 μM Indomethacin
SYNTHESIS OF DNA 84 1,868 0,254
DNA STRAND ELONGATION 29 1,851 0,148
S PHASE 101 1,848 0,113
SIGNALING BY WNT 64 1,597 0,249
DOWNSTREAM TCR SIGNALING 35 1,590 0,244
25 μM Nimesulide
ACTIVATION OF THE MRNA UPON BINDING OF 
THE CAP BINDING COMPLEX AND EIFS AND 
SUBSEQUENT BINDING TO 43S
60 1,817 0,208
FORMATION OF THE TERNARY COMPLEX AND 
SUBSEQUENTLY THE 43S COMPLEX 50 1,768 0,199
SYNTHESIS AND INTERCORVERSION OF 
NUCLEOTIDE DI AND TRIPHOSPHATES 19 1,721 0,237
TRANSLATION 155 1,711 0,199
YAP1 AND WWTR1 TAZ STIMULATED GENE 
EXPRESSION 24 1,707 0,168
SRP DEPENDENT COTRANSLATIONAL PROTEIN 
TARGETING TO MEMBRANE 115 1,706 0,147
UTR MEDIATED TRANSLATIONAL REGULATION 112 1,693 0,138
METABOLISM OF PROTEINS 441 1,666 0,158
REGULATION OF KIT SIGNALING 17 1,654 0,159
ANTIGEN PRESENTATION FOLDING ASSEMBLY 
AND PEPTIDE LOADING OF CLASS I MHC 20 1,653 0,148
INFLUENZA LIFE CYCLE 140 1,636 0,161
SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 
7ALPHA HYDROXYCHOLESTEROL 15 1,599 0,196
CITRIC ACID CYCLE TCA CYCLE 23 1,597 0,190
OXYGEN DEPENDENT PROLINE 
HYDROXYLATION OF HYPOXIA INDUCIBLE 
FACTOR ALPHA
17 1,589 0,193
PEPTIDE CHAIN ELONGATION 90 1,585 0,184
TRANSPORT TO THE GOLGI AND SUBSEQUENT 
MODIFICATION 33 1,577 0,180
NONSENSE MEDIATED DECAY ENHANCED BY 
THE EXON JUNCTION COMPLEX 111 1,575 0,176
EARLY PHASE OF HIV LIFE CYCLE 18 1,554 0,207
INFLUENZA VIRAL RNA TRANSCRIPTION AND 
REPLICATION 106 1,554 0,199
Table 2.  Table of selective gene sets enriched among genes significantly up-regulated (FC ≥ 1.3) by 10 μM 
indomethacin or 25 μM nimesulide after 24 h treatment of HDFa cells based on GSEA of Reactome pathway 
expression (NES, normalized enrichment score; FDR q-val < 0.25, q value of false discovery rate, and p-val  
< 0.01), with the signal transduction cascades and DNA and protein metabolism gene sets at the top.
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deregulation of all types of glycosaminoglycans due to EGF receptor signaling cascades’ inhibition. In addition, in 
the case of cell treatment with NSAIDs, substances responsible for depletion of cellular sulphates, only sulphated 
GAGs (i.e. heparan sulfate, dermatan sulfate, chondroitin sulfate and keratan sulfate) seemed to be deregulated. 
Sulphates are basic and indispensable building blocks of GAGs. With the exception of hyaluronate, all glycos-
aminoglycans contain sulphate groups in ester linkages with the hydroxyl groups of the amino sugar residues. 
Nevertheless, in future study detailed quantification of every GAG individually will be of interest.
Summing up, the results presented in this work suggest that some of the non-steroidal anti-inflammatory 
drugs, and their combinations with isoflavone genistein, can be considered as a method for improvement of 
efficiency of therapy for mucopolysaccharidoses, especially their neurological forms. It is believed that our inves-
tigations can provide new information regarding the molecular mechanism of action of substances decreasing 
the synthesis of compounds being pathologically accumulated in the cells of people suffering from various types 
of genetically determined lysosomal storage diseases. On the other hand, proper choice of conditions of the 
drug applications are not trivial, and extensive studies are necessary for optimization of each particular com-
bined treatment. Previous studies documented preliminary experiments with genistein-based SRT called GET-IT 
combined with ERT on MPS I culture cells as an effective approach30. Currently, the results of our studies on 
this kind of approach on MPS mouse models, conducted within the framework of another large research grant, 
are very promising. The same can be presumed on the development of a high efficacy of NSAID and ERT or 
HSCT combined therapies for MPSs, representing a promising method in indications of unmet medical needs. 
Understanding of these issues may result in serious progress in therapeutic approaches.
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